{"transactions":[{"id":1962931,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-08T16:26:13.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":690,"price":15.2634,"value":10531.746,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":268854,"source":{"system":"sec-edgar","filing":"0001567619-23-004668","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761923004668/doc1.xml","form_type":"4"}},{"id":1968632,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-06T18:56:49.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":39500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":39500,"derivative":{"exercise_price":15.82,"expiration_date":"2033-03-02","underlying":"Common Stock","underlying_shares":39500},"source":{"system":"sec-edgar","filing":"0001567619-23-004545","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761923004545/doc1.xml","form_type":"4"}},{"id":1968631,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-06T18:56:49.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":14900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":269544,"source":{"system":"sec-edgar","filing":"0001567619-23-004545","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761923004545/doc1.xml","form_type":"4"}},{"id":1979000,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-02T19:03:55.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":15,"price":16.52,"value":247.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":254644,"source":{"system":"sec-edgar","filing":"0001567619-23-004268","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761923004268/doc1.xml","form_type":"4"}},{"id":1978999,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-02T19:03:55.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":1198,"price":15.8185,"value":18950.563,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":254659,"source":{"system":"sec-edgar","filing":"0001567619-23-004268","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761923004268/doc1.xml","form_type":"4"}},{"id":1978998,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-02T19:03:55.000Z","date":"2023-02-28","kind":"sale","acquired":false,"shares":792,"price":16.1663,"value":12803.7096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":255857,"source":{"system":"sec-edgar","filing":"0001567619-23-004268","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761923004268/doc1.xml","form_type":"4"}},{"id":2208499,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-07-12T19:30:56.000Z","date":"2022-07-08","kind":"sale","acquired":false,"shares":2197,"price":25.4144,"value":55835.4368,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $25.00 to $25.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 24,925 RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects the adjusted total which includes the purchase of 1,617 shares under the Arcutis Employee Stock Purchase Plan on May 31, 2022."}],"balance_after":256649,"source":{"system":"sec-edgar","filing":"0001567619-22-013925","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761922013925/doc1.xml","form_type":"4"}},{"id":2292595,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-04-21T18:32:59.000Z","date":"2022-04-21","kind":"sale","acquired":false,"shares":2197,"price":20.4243,"value":44872.1871,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $20.125 to $20.925, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 24,925 RSUs."}],"balance_after":257229,"source":{"system":"sec-edgar","filing":"0001567619-22-008817","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761922008817/doc1.xml","form_type":"4"}},{"id":2347380,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-07T20:47:27.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":35300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":35300,"derivative":{"exercise_price":17.67,"expiration_date":"2032-03-03","underlying":"Common Stock","underlying_shares":35300},"source":{"system":"sec-edgar","filing":"0001567619-22-006492","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761922006492/doc1.xml","form_type":"4"}},{"id":2347379,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-03-07T20:47:27.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":28,"price":16.4449,"value":460.4572,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $16.44 to $16.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 24,925 RSUs."}],"balance_after":259426,"source":{"system":"sec-edgar","filing":"0001567619-22-006492","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761922006492/doc1.xml","form_type":"4"}},{"id":2347378,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-03-07T20:47:27.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":828,"price":16.8591,"value":13959.3348,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $16.63 to $17.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":259454,"source":{"system":"sec-edgar","filing":"0001567619-22-006492","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761922006492/doc1.xml","form_type":"4"}},{"id":2347377,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-03-07T20:47:27.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":260282,"source":{"system":"sec-edgar","filing":"0001567619-22-006492","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761922006492/doc1.xml","form_type":"4"}},{"id":2353458,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T16:18:11.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":775,"price":17.7527,"value":13758.3425,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,004 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 976 shares on May 31, 2021 and 28 shares on November 30, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 14,000 RSUs."}],"balance_after":246982,"source":{"system":"sec-edgar","filing":"0001567619-22-006229","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761922006229/doc1.xml","form_type":"4"}},{"id":2805548,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-05T15:52:49.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":28800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":28800,"derivative":{"exercise_price":32.44,"expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":28800},"source":{"system":"sec-edgar","filing":"0001567619-21-005731","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761921005731/doc1.xml","form_type":"4"}},{"id":2805547,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-03-05T15:52:49.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2022, subject to the Reporting Person's continued service to the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 16,250 RSUs."}],"balance_after":246753,"source":{"system":"sec-edgar","filing":"0001567619-21-005731","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761921005731/doc1.xml","form_type":"4"}},{"id":2812198,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-03-03T16:50:11.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":780,"price":34.574,"value":26967.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,750 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":237253,"source":{"system":"sec-edgar","filing":"0001567619-21-005542","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761921005542/doc1.xml","form_type":"4"}},{"id":2858611,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-02-16T19:29:31.000Z","date":"2020-12-18","kind":"gift","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 9,000 Restricted Stock Units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":238033,"source":{"system":"sec-edgar","filing":"0001567619-21-004140","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761921004140/doc1.xml","form_type":"5"}},{"id":2942120,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-12-16T15:15:38.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":15000,"price":30,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,000 Restricted Stock Units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,254 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 1,038 shares on May 31, 2020 and 216 shares on November 30, 2020."}],"balance_after":250533,"source":{"system":"sec-edgar","filing":"0001567619-20-021191","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761920021191/doc1.xml","form_type":"4"}},{"id":3018231,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-10-01T21:01:34.000Z","date":"2020-09-29","kind":"sale","acquired":false,"shares":15000,"price":30,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,000 Restricted Stock Units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":264279,"source":{"system":"sec-edgar","filing":"0001567619-20-017382","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761920017382/doc1.xml","form_type":"4"}},{"id":3231394,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-03T21:06:24.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024."}],"balance_after":12000,"derivative":{"exercise_price":27.61,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001567619-20-005548","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761920005548/doc1.xml","form_type":"4"}},{"id":3231393,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-03-03T21:06:24.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSU\"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024."}],"balance_after":279279,"source":{"system":"sec-edgar","filing":"0001567619-20-005548","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000156761920005548/doc1.xml","form_type":"4"}},{"id":3291059,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Series A Preferred Stock","published_at":"2020-02-04T18:24:36.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":24991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24991},"source":{"system":"sec-edgar","filing":"0001209191-20-006595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000120919120006595/doc4.xml","form_type":"4"}},{"id":3291058,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":115782,"kind":"person","name":"OSBORNE DAVID W","position":1,"cik":"0001252999","reported_name":"OSBORNE DAVID W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-02-04T18:24:36.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":24991,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."}],"balance_after":270279,"source":{"system":"sec-edgar","filing":"0001209191-20-006595","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252999/000120919120006595/doc4.xml","form_type":"4"}}]}